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newly diagnosed FLT3-mutated AML patient 60 years was estimated at $114,193
compared to $105,819 for patients with non-FLT3-mutated AML. As early mortality
and early retirement were not included in indirect costs, these may be
underestimated. CONCLUSIONS: FLT3-mutated AML potentially represents a
greater per-patient burden than non-FLT3-mutated AML due to shorter survival
and greater use of stem cell transplants. Investigational treatments targeting the
FLT3 mutation may provide an additional therapeutic option and have the poten-
tial to improve clinical outcomes.
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OBJECTIVES: Hemophilia patients frequently experience joint bleeding, resulting
in persistent pain and arthropathy. The objective of this study was to determine
drivers of total and hemophilia-related costs among hemophilia patientswith joint
pain.METHODS: InVision™ Data Mart (OptumInsight Life Sciences, 1/2005-3/2009)
was used to identify male patients with hemophilia A/B (ICD-09 286.0 and 286.1)
who were treated with FVIII/FIX/bypassing agent and had  2 years of continuous
enrollment from index. Patients were stratified into severe joint pain (SJP), 2 joint
pain claims (ICD-9 713, 715, 716, 718, 719, 727) 12 months pre or 6 months post
index, andminimal joint pain (MJP), 2 pain claims. Cohorts werematched on age,
treatment type and Charlson comorbidity scores via propensity scoring. Random
forest analysis informed covariate selection for log-transformed linear regression
models. Covariate selection was further refined based on variance inflation, vari-
able significance and medical relevance. RESULTS: A total of 284 patients (142 SJP,
142 MJP); mean age30 years were identified. Mean (median) total cost of all pa-
tients was $630K ($248K) over a 2-year period but were significantly higher for SJP-
$917K compared to MJP- $354K (p0.01). Hemophilia therapy was the main driver
of total patient cost (p0.0001). Home health visits (p0.0001), hemophilia-related
hospital visits (p0.0001) and age (p0.01) were also significant drivers of SJP costs.
Removal of covariates measuring factor therapy or claims with hemophilia diag-
noses showed that joint pain claims (p0.01), injectible medications (p0.01),
Charlson Comorbidity Index (p0.01), non-hemophilia lab tests (p0.01), anti-in-
fective medications (p0.01), and age (p0.001) were significantly related to total
patient cost.CONCLUSIONS:The treatment of joint painmarks significantly higher
hemophilia costs, however, some of these differences may be attributed to hemo-
philia severity (not coded within ICD-9). Modification of ICD-9 codes may help
understand economics among hemophilia patients in the future.
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OBJECTIVES: Postherpetic neuralgia (PHN) is a painful, chronic condition. Gabap-
entin and pregabalin are common first-line medications for PHN and must be
titrated over time to effective doses. Individuals with PHN may augment therapy
with opioids to control pain. Pain management for PHN can require substantial
healthcare resources. The study objective was to evaluate costs for persons with
PHN. METHODS: This retrospective claims database analysis used medical and
pharmacy claims data and enrollment information for adult commercial andMedi-
care Advantage enrollees in a large, national US health plan. Patients had1 phar-
macy claim for gabapentin or pregabalin from January 2006–February 2009; the
date of the first claimwas the index date. Patients also had diagnosis codes for PHN
(ICD-9-CM 053.1x) on or within 2 days after the index date; and 6-month and 12-
month pre- and post-index periods, respectively, during which they were contin-
uously enrolled. Total medical, outpatient pharmacy, and health care (medical 
pharmacy) post-index costs per patient with PHN per month were compared be-
tween gabapentin and pregabalin cohorts. RESULTS: The study population com-
prised 1645 patients, 939 in the gabapentin cohort and 706 in the pregabalin cohort;
77.6% were commercial enrollees and 22.4% were Medicare Advantage enrollees.
The mean (standard deviation) monthly healthcare costs were $1,749 ($6,117) for
the gabapentin cohort and $1,570 ($4,935) for the pregabalin cohort (p0.512).Mean
monthly medical costs were $1326 ($5831) in the gabapentin cohort and $985
($4,753) in the pregabalin cohort (p0.192). The pregabalin cohort had highermean
monthly pharmacy costs ($585 [$727]) than did the gabapentin cohort ($423 [$755],
p0.001). CONCLUSIONS: Health care costs for patients with PHN are substantial:
approximately $1700 per person with PHN per month, and approximately $20,000
per year. Health care costs between the gabapentin and pregabalin cohorts were
not significantly different despite significantly different mean pharmacy costs.
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OBJECTIVES: Prior research evaluated the impact of infliximab (IFX) adherence on
resource use and costs in Crohn’s disease (CD). Purpose was to examine the asso-
ciation between adherence and all-cause healthcare costs among those who are
treatedwith IFX for inflammatory bowel disease (IBD).METHODS: Patients with1
claims for IFX initiated between January 1, 2006 to December 31, 2009 who had 2
IBD diagnoses of Crohn’s disease (CD; ICD-9-CM: 555.XX) or ulcerative colitis (UC;
ICD-9-CM: 556.XX) during the pre-index period were identified from Thomson Reu-
ters Marketscan® Databases. Patients had to be 18 years, continuously enrolled for
12 months before and after IFX initiation, and had no prior use of IFX during 360-
days pre-index. Patients with prior biologic therapy or rheumatoid arthritis (ICD-
9-CM: 714.XX) were excluded. Adherent group was classified as having a medica-
tion possession ratio (MPR) of 80%; non-adherent group had an MPR80%.
Differences between the adherent and non-adherent groups were assessed using
propensity-weighted general linear models. RESULTS: A total of 1,646 IBD patients
were identified (945 CD; 701 UC) with a mean (SD) age of 44.4 (15.6) and 48.3% were
female. Of these, 41% were adherent and 59% were non-adherent. Propensity-
weighted mean total healthcare costs excluding IFX were $13,424 vs. $32,522
(P0.0001) for the adherent vs. non-adherent groups. Mean all-cause component
costs were $2,458 vs. $17,634 (P0.0001) for hospitalizations, $7,357 vs. $10,909
(P0.0001) for outpatient visits, and $236 vs. $458 (P0.0001) for ER visits in the
adherent vs. non-adherent groups, respectively; total costs (component IFX)were
also significantly lower in the adherent group. No significant differences were ob-
served in other prescription costs. CONCLUSIONS: Medication adherence was as-
sociated with significantly lower total healthcare costs in patients treated with IFX
for IBD. These differencesmay be explained by reducedhospitalization, outpatient,
and ER costs observed in the adherent vs. non-adherent groups.
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OBJECTIVES: Little data are available on the burden of ASM, a subtype of systemic
mastocytosis (SM) and severe form of mast cell disease that may progress to mast
cell leukemia. This study reviewed the literature in order to estimate the burden of
ASM in theUS.METHODS:Asystematic literature reviewwas conducted to identify
publications from2000-2011; 181 citationswere identified and 6 articles abstracted.
TheUS population-level burden of ASMwas estimated using an Excelmodel. Direct
treatment costs were calculated from treatment patterns described in identified
publications. RESULTS: ASM involves multiple organ systems, resulting in poten-
tially severe symptoms/conditions including anaphylaxis/allergic reactions, osteo-
porosis, hepatomegaly, splenomegaly, gastrointestinal symptoms, fatigue, and
weight loss. There is no known cure for ASM. Median survival was 41 months in a
published cohort study. No publicationswere identified providingUS epidemiology
data. Two estimates were calculated for the prevalence of ASM in the US in 2010:
616 and 1,220. A global prevalence rate of 0.2/100,000 resulted in 616 cases. An SM
prevalence rate of 3.3/100,000 (assuming 12% ASM) resulted in 1,220 cases. Inci-
dence was estimated at 111 cases in 2010 using an SM incidence rate of 0.3/100,000
(assuming 12% ASM). The proportion of ASM/SM cases ranged from 7-18% in the
literature with 12% from the largest study. No studies were identified examining
the economic burden of ASM. In this model, direct monthly per-patient costs were
estimated between $5232 and $8741. These are likely underestimated as a result of
limited resource utilization information in the literature. CONCLUSIONS: These
results provide preliminary estimates for the burden of ASM in the UNITED
STATES. Additional research can assist in further quantifying these estimates. In
addition, it is likely that ASM patients experience tremendous indirect costs due to
the symptomatic burden of the disease and further evaluation is warranted.
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OBJECTIVES: To evaluate the association of patient cost or reimbursement chal-
lenges with healthcare resource utilization, quality of life (QoL), and work produc-
tivity among patients with inflammatory bowel disease (IBD).METHODS: A syndi-
cated study of IBD patients in the USwas conducted. Patients18 years of agewere
recruited via the National Health and Wellness Survey and Lightspeed Research
Panel. Patients completed a survey during August–November 2010 in which they
were asked if they experienced cost or reimbursement challenges related to pre-
scription medication. The Medical Outcomes Study (MOS) IBD questionnaire was
used to assess QoL. Work productivity was assessed using the Work Productivity
and Activity Impairment (WPAI) questionnaire. To measure health care resource
utilization, the number of provider, emergency room (ER) and hospital visits in the
past six months was collected. Bivariate differences between the patient groups
(those with cost or reimbursement issues versus those without) for resource utili-
zation, QoL, and work impairment were assessed using chi-square tests for cate-
gorical variables and t-tests for continuous variables. RESULTS: Of 1098 IBD pa-
tients currently receiving prescription medication, 21% (n231) reported that cost
had previously prevented them from taking medication. Among patients who had
ever taken prescription medication (n1343), 13% (n178) reported ever having a
problem getting reimbursed for medication. Sixty-eight of these patients (38%)
indicated theirmedicationwas not covered by insurance. Patients reporting cost or
reimbursement issues had a higher probability of having provider, ER and hospital
visits in the prior six months (all p0.05). Furthermore, these patients reported
greater work impairment and lower QoL (both p0.05). CONCLUSIONS:Among IBD
patients, cost or reimbursement challenges may be associated with more resource
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utilization, lower QoL and greater work impairment. Additional research is war-
ranted to further characterize the impact of cost and reimbursement on patient
outcomes.
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OBJECTIVES: Limited data exist on the economic impact of SLE flares. This study
estimatedHRUand costs of SLE flares in aU.S.Medicaid population.METHODS: SLE
Patients 18 years old were extracted from a large Medicaid database 2002-2009.
Index date was the date of the first SLE diagnosis. All patients were continuously
enrolled for6months before and12months after index date and followed until
the earliest of inpatient death, end of enrollment, or end of study. Mild, moderate,
and severe flareswere identified in the follow-up period. Costs attributable to flares
weremeasured during 30 days following a flare. If a flare of higher severity occurred
within 30 days, the length was limited to the period up to the start of the new flare.
RESULTS: 14,262 patients met the study criteria and 97% experienced at least one
flare during an average follow-up of 39 months (3,540 had severe, 9,597 had mod-
erate, and 669 hadmild flares as theirmost severe flares). Mean costs per flarewere
$11,716, $562 and $129 for severe, moderate, and mild flares, respectively. Patients
with 1 severe flares during follow-up had 1.7 inpatient (IP) admissions, 3.5 emer-
gency room (ER) visits, and 16.0 outpatient (OP) visits with a total medical cost of
$49,754per year. Patients with 1 moderate flares but no severe flares had 0.9 IP
admissions, 2.4 ER visits, and 12.8 OP visitswith a cost of $21,941. Patientswith only
mild flares had the least HRU of 1.0 IP admission, 1.5 ER visits, and 7.5 OP visits with
a cost of $17,574. Patients with severe andmoderate but nomild flares and patients
with severe flares only incurred the highest annual cost ($66,412 and $74,491,
respectively). CONCLUSIONS: Flares occurred in almost all SLE patients and were
associated with a significant economic burden.
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OBJECTIVES: Immune tolerance induction (ITI) is generally accepted as first choice
treatment to eradicate inhibitors in hemophilia A patients. Little is known about
the outcomes and cost consequences of this treatment option. METHODS: The
Immune Tolerance and Economics Retrospective (ITER) study is an observational,
retrospective, multicentre, multinational study aiming to estimate cost of treat-
ment in hemophilia A patients, undergoing ITI. Data on hemostatic treatment
given in the following time periods were collected: up to 12 months before the
diagnosis of Inhibitors, between Inhibitors diagnosis and ITI start, during ITI, and
12 months after the end of ITI. Costs of treatment were calculated in the perspec-
tive of the third party payer and expressed as mean €/patient-month. RESULTS:
Seventy-one valid patients, with median age at ITI start3.8 (0.4-41) years, were
enrolled. Before ITI the median Inhibitors peak titre was 18.5 (0.80-704) BU. ITI was
applied for a mean of 1.85 (0.1-14.0) years and was successful in 84.5% pts. Before
Inhibitors diagnosis, patients cost was 670.2 €/patient-month. Cost was 3,188€/
patient-month between the Inhibitors diagnosis and ITI start (92.1% for bypassing
agents), and 60,078€ during ITI (76.8% for ITI, 19.4% for extra FVIII treatment, 3.8%
for extra treatment with bypassing agents). The mean cost after ITI was
13,211€/patient-month. CONCLUSIONS: ITI applied on patients with the character-
istics of those involved in the ITER study is successful in 84% of themat amean cost
of 60,000€/patient-month during ITI, plus 13,000€/patient-month through 1 year
later. Further research is encouraged to value long term benefits and costs attrib-
utable to ITI versus other treatment options, in order to identify the most efficient
treatment for the patients and for the health care system.
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OBJECTIVES: Limited information is available on the cost effectiveness of newer
biologic agents for treatment of psoriasis. The objective of this study is, from a
United States societal perspective, to compare the cost-effectiveness of etanercept
and ustekinumab therapy in patients with moderate-to-severe psoriasis based on
head-to-head clinical trial information. METHODS: A Markov model was con-
structed to simulate the incremental cost per quality-adjusted life year gained.
Costs were estimated from the societal perspective in the United States over a time
horizon of five years. All cost and effectiveness estimates were obtained from the
relevant literature. An annual discount rate of 3%was applied to costs and quality-
adjusted life years. All costs were adjusted to 2011 US dollars. One-way and thresh-
old sensitivity analyses assessed the robustness of model results. RESULTS: In the
base case, over a 5-year time horizon, ustekinumab 45 mg was dominant versus
etanercept 50 mg. The base case incremental cost-effectiveness ratio (ICER) com-
paring ustekinumab 90 mg with etanercept 50 mg averaged $267,761 per QALY
gained. The ICER comparing ustekinumab 90mgwith ustekinumab 45mgaveraged
$915,179 per QALY gained. ICERs were quite sensitive to unit prices for usteki-
numab and etanercept. CONCLUSIONS: Given the limitations of the available data,
ustekinumab 45 mg was dominant over etanercept 50 mg for a five-year time
horizon, whereas ustekinumab 90 mg was more costly and marginally more effec-
tive than etanercerpt 50 mg. Ustekinumab 90 mg would not be considered cost
effective using a US willingness-to-pay threshold of $120,000-150,000 per QALY.
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OBJECTIVES: Patients with chronic pain due to osteoarthritis (OA) or rheumatoid
arthritis (RA) do not often obtain adequate relief or experience unacceptable side
effects due their pain-control treatments. The objective of this study was to per-
form a cost-effectiveness analysis comparing celecoxib, etoricoxib and lumira-
coxib in the treatment of chronic pain in patients with OA and RA, from the Mex-
ican Social Security Institute (IMSS) perspective.METHODS: A decision-tree model
(12-weeks time horizon) was used to compare pain reduction and direct medical
costs associated to competing alternatives. A systematic literature reviewwas per-
formed to identify the pain reduction (reported through visual analogue scales) and
adverse events (AE) incidence rate associated. Comparatorswere: celecoxib 200mg/
day, etoricoxib 90mg/day and lumiracoxib 100mg/day for patients with OA and RA.
A meta-analysis with selected publications (n10) was performed. Resource utili-
zationwas extracted from clinical practice guidelines and unit costswere retrieved
from IMSS official sources. Probabilistic sensitivity analysis was performed. Ac-
ceptability curves were developed. RESULTS: Pain reductions vs. placebo were:
celecoxib 14.18% (CI95% 10.48-17.87, p0.00001); etoricoxib 12.70% (7.67-17.73,
p0.00001) and lumiracoxib 9.47% (7.17-11.77, p0.00001). Differences between
celecoxib and lumiracoxib was meaningful (p0.05). The odds ratios of AE inci-
dence vs. placebo were: 1.06 (0.77-1.46, p0.37); 1.09 (0.87-1.36, p0.73) and 1.44
(0.88-2.34, p0.14), respectively. The expected medical costs (2011 US$) were:
$197.93 ($9.52); $221.54 ($7.06) and $306.65 ($12.86), respectively. The cost of
management of AE contributed with $101.28, $95.00 and $146.17 of the overall
expected costs, respectively. In regards to etoricoxib (basecase), celecoxib showed
to be a cost-saving strategy with a cost-effective proportion of 76.7% (74.1%-79.3%);
while lumiracoxib was the less effective and more costly strategy. CONCLUSIONS:
At IMSS, celecoxib patients who suffer OA or RA would reach a higher incremental
reduction in pain intensity at 12 weeks reducing overall costs in comparison to
etoricoxib.
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OBJECTIVES: In the French setting, uncontrolled bleeding episodes in hemophilia
patients with inhibitors require emergency/inpatient care. The impact of on-de-
mand (OD) treatment of bleeding episodes remain rarely quantified in France.
METHODS:Wemodeled the lifetime number of bleeding episodes and hospitaliza-
tions associated with recombinant activated Factor VIIa (rFVIIa) and plasma-de-
rived activated prothrombin complex concentrate (pd-aPCC) to investigate the im-
pact of faster bleeding resolution of a new bypassing agent (BA) by applying
hypothetical adjustments to the performance of rFVIIa. The exploratory semi-
Markov model assumed a French payer perspective and simulated treatment of
2-year oldmale hemophilia patientswith high-responding inhibitors.Model inputs
were obtained from published international studies and French government
sources. Comparisons of the current BAs pertaining to dosing and base-case effi-
cacy rates were obtained from a Bayesian meta-analysis pooling available esti-
mates. Model outcomes included the rate of hospitalization due to uncontrolled
bleeds and number of minor/major bleed over lifetime. Sensitivity analyses were
performed to test robustness of the model. RESULTS: rFVIIa required 4% fewer
hospitalizations for bleed treatment than pd-aPCC, as well as a reduction in life-
time bleeds. rFVIIa resulted in 667 minor bleeds over the patient’s lifetime com-
pared with 673 in patients treated with pd-aPCC. When adopting potential im-
provements for a hypothetical new BA, faster bleed resolution that results in fewer
rebleeds reduces hospitalizations by 13% in the rFVIIa arm compared to base case.
CONCLUSIONS: Additional research is needed to understand how increased bleed
control and faster resolution of bleeds in French inhibitor patients translate into a
reduction in other health resources utilization such as emergency visits to hemo-
philia treatment centers and indirect costs including missed school/productivity
loss which can improve the quality of life of patients and caregivers.
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